Financial results: Avecho; Wellnex; Zelira; Emyria; Botanix; MGC Pharma; AusCann; Epsilon; Melodiol; Bioxyne
Avecho Biotechnology saw revenue from ordinary activities fall 41% to A$446k in the half year...
- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)